Otolin-1 as a biomarker for the evaluation of the effectiveness of betahistine treatment for benign paroxysmal positional vertigo

References

• Kim JS, Zee DS. Clinical practice. Benign paroxysmal positional vertigo. N Engl J Med. 2014;370(12):1138–1147. doi: 10.1056/NEJMcp1309481.
   PubMed Web of Science ®Google Scholar
• Hall SF, Ruby RR, McClure JA. The mechanics of benign paroxysmal vertigo. J Otolaryngol. 1979;8:151–158.
   PubMedGoogle Scholar
• Kim HJ, Park J, Kim JS. Update on benign paroxysmal positional vertigo. J Neurol. 2021;268(5):1995–2000. doi: 10.1007/s00415-020-10314-7.
   PubMed Web of Science ®Google Scholar
• Brandt T, Steddin S. Current view of the mechanism of benign paroxysmal positioning vertigo: cupulolithiasis or canalolithiasis? J Vestib Res. 1993;3(4):373–382.
   PubMedGoogle Scholar
• Obrist D, Hegemann S, Kronenberg D, et al. In vitro model of a semicircular canal: design and validation of the model and its use for the study of canalithiasis. J Biomech. 2010;43(6):1208–1214. doi: 10.1016/j.jbiomech.2009.11.027.
   PubMed Web of Science ®Google Scholar
• Byun H, Chung JH, Lee SH, et al. Increased risk of benign paroxysmal positional vertigo in osteoporosis: a nationwide population-based cohort study. Sci Rep. 2019;9(1):3469. doi: 10.1038/s41598-019-39830-x.
   PubMedGoogle Scholar
• Shih CP, Wang CH, Chung CH, et al. Increased risk of benign paroxysmal positional vertigo in patients with non-apnea sleep disorders: a nationwide, population-based cohort study. J Clin Sleep Med. 2018;14(12):2021–2029. 15doi: 10.5664/jcsm.7528.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang S, Cui K, et al. Risk factors for benign paroxysmal positional vertigo recurrence: a systematic review and meta-analysis. J Neurol. 2021;268(11):4117–4127.
   PubMed Web of Science ®Google Scholar
• Deans MR, Peterson JM, Wong GW. Mammalian otolin: a multimeric glycoprotein specific to the inner ear that interacts with otoconial matrix protein otoconin-90 and cerebellin-1. PLoS One. 2010;5(9):e12765. doi: 10.1371/journal.pone.0012765.
   PubMed Web of Science ®Google Scholar
• Wu Y, Han W, Yan W, et al. Increased otolin-1 in serum as a potential biomarker for idiopathic benign paroxysmal positional vertigo episodes. Front Neurol. 2020;11:367. doi: 10.3389/fneur.2020.00367.
   PubMed Web of Science ®Google Scholar
• Agus S, Benecke H, Thum C, et al. Clinical and demographic features of vertigo: findings from the REVERT registry. Front Neurol. 2013;4:48. doi: 10.3389/fneur.2013.00048.
   PubMed Web of Science ®Google Scholar
• Barak N. Betahistine: what’s new on the agenda? Expert Opin Investig Drugs. 2008;17(5):795–804. doi: 10.1517/13543784.17.5.795.
   PubMed Web of Science ®Google Scholar
• Timmerman H. Pharmacotherapy of vertigo: any news to be expected? Acta Otolaryngol Suppl. 1994;513:28–32. doi: 10.3109/00016489409127323.
   PubMedGoogle Scholar
• von Brevern M, Bertholon P, Brandt T, et al. Benign paroxysmal positional vertigo: diagnostic criteria. J Vestib Res. 2015;25(3,4):105–117. doi: 10.3233/VES-150553.
   PubMed Web of Science ®Google Scholar
• Whitney SL, Marchetti GF, Morris LO. Usefulness of the dizziness handicap inventory in the screening for benign paroxysmal positional vertigo. Otol Neurotol. 2005;26(5):1027–1033. doi: 10.1097/01.mao.0000185066.04834.4e.
   PubMed Web of Science ®Google Scholar
• Mutlu B, Serbetcioglu B. Discussion of the dizziness handicap inventory. J Vestib Res. 2013;23(6):271–277. doi: 10.3233/VES-130488.
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang H, Yamoah EN, et al. Gene targeting reveals the role of Oc90 as the essential organizer of the otoconial organic matrix. Dev Biol. 2007;304(2):508–524. doi: 10.1016/j.ydbio.2007.01.013.
   PubMed Web of Science ®Google Scholar
• Cavaliere M, Mottola G, Iemma M. Benign paroxysmal positional vertigo: a study of two maneuvers with and without betahistine. Acta Otorhinolaryngol Ital. 2005;25(2):107–112.
   PubMedGoogle Scholar
• Parfenov VA, Golyk VA, Matsnev EI, et al. Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: the VIRTUOSO study. PLOS One. 2017;12(3):e0174114. doi: 10.1371/journal.pone.0174114.
   PubMed Web of Science ®Google Scholar
• van Vugt VA, van der Horst HE, Payne RA, et al. Chronic vertigo: treat with exercise, not drugs. BMJ. 2017;358:j3727. doi: 10.1136/bmj.j3727.
   PubMedGoogle Scholar
• Meyer P, Schmidt R, Grützmacher W, et al. Die innenohrdurchblutung unter betahistin-eine tierexperimentelle studie [Inner ear blood flow with betahistine–an animal experiment study]. Laryngorhinootologie. 1994;73(3):153–156. doi: 10.1055/s-2007-997100.
   PubMedGoogle Scholar
• Dziadziola JK, Laurikainen EL, Rachel JD, et al. Betahistine increases vestibular blood flow. Otolaryngol Head Neck Surg. 1999;120(3):400–405. doi: 10.1016/S0194-5998(99)70283-4.
   PubMed Web of Science ®Google Scholar
• Ihler F, Bertlich M, Sharaf K, et al. Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in Guinea pigs in vivo. PLOS One. 2012;7(6):e39086. doi: 10.1371/journal.pone.0039086.
   PubMed Web of Science ®Google Scholar
• Yang X, Yang B, Wu M, et al. Association between serum uric acid levels and benign paroxysmal positional vertigo: a systematic review and meta-analysis of observational studies. Front Neurol. 2019;10:91. doi: 10.3389/fneur.2019.00091.
   PubMed Web of Science ®Google Scholar
• Tabtabai R, Haynes L, Kuchel GA, et al. Age-related increase in blood levels of otolin-1 in humans. Otol Neurotol. 2017;38(6):865–869. doi: 10.1097/MAO.0000000000001426.
   PubMed Web of Science ®Google Scholar